Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal

Novo Nordisk A/S (NVO) announced positive top-line results from its late-stage COMBINE 3 study evaluating once-weekly IcoSema in 679 people with type II diabetes inadequately controlled on daily basal insulin.The company’s investigational candidate, IcoSema, is a fixed-ratio combination of basal insulin icodec and semaglutide.The 52-week phase IIIa COMBINE 3 study is comparing the efficacy and safety of once-weekly IcoSema against once-daily insulin glargine U100 and insulin aspart (injected two to four tim ...